fludarabine has been researched along with Chronic Disease in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (5.36) | 18.2507 |
| 2000's | 26 (46.43) | 29.6817 |
| 2010's | 25 (44.64) | 24.3611 |
| 2020's | 2 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Aotsuka, N; Hangaishi, A; Hoshino, T; Kako, S; Kanda, Y; Kato, J; Kobayashi, T; Matsumoto, K; Mori, T; Najima, Y; Okamoto, S; Onizuka, M; Shimizu, H; Shono, K; Tachibana, T; Tanaka, M; Tsukamoto, S; Usuki, K; Watanabe, R; Yamazaki, E; Yano, S | 1 |
| Araqi Houssaini, L; Chiheb, S; Hali, F; Marnissi, F; Quessar, A | 1 |
| Baek, S; Choi, EJ; Choi, Y; Jeon, M; Jo, JC; Joo, YD; Kang, YA; Kang, YL; Kim, DY; Kim, H; Kim, SH; Ko, SH; Lee, JH; Lee, KH; Lee, YS; Lim, SN; Park, HS; Seol, M; Yun, SC | 1 |
| Chen, Y; Feng, J; Lin, F; Lu, N; Ma, Y; Shi, Y; Sun, L; Tang, L; Wang, N; Xing, C; Yu, K | 1 |
| Blaise, D; Bramanti, S; Calmels, B; Castagna, L; Chabannon, C; Charbonnier, A; Devillier, R; Faucher, C; Fürst, S; Granata, A; Harbi, S; Hospital, MA; Legrand, F; Lemarie, C; Lining, W; Maisano, V; Mokart, D; Pagliardini, T; Porta, MD; Rey, J; Saillard, C; Vey, N; Weiller, PJ | 1 |
| Barrett, J; Childs, RW; Cook, L; Donohue, T; Geller, N; Khuu, H; Kurlander, R; Leitman, S; Pantin, J; Ramos, C; Shah, AA; Stroncek, D; Tian, X; Young, NS | 1 |
| Blaise, D; Castagna, L; Chabannon, C; Crocchiolo, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Lemarie, C; Oudin, C; Saillard, C; Signori, A | 1 |
| Blaise, D; Bouabdallah, R; Broussais-Guillaumot, F; Calmels, B; Castagna, L; Chabannon, C; Charbonnier, A; Crocchiolo, R; Devillier, R; El-Cheikh, J; Fürst, S; Granata, A; Harbi, S; Lemarie, C; Mohty, B; Oudin, C; Rey, J; Stoppa, AM; Vey, N | 1 |
| Abedin, S; Choi, S; Couriel, DR; Levine, JE; Peres, E; Yanik, G | 1 |
| Chang, TY; Chen, SH; Hsueh, C; Hung, IJ; Jaing, TH; Yang, CP | 1 |
| Cassaday, RD; Flowers, ME; Gopal, AK; Green, DJ; Guthrie, KA; Maloney, DG; Pagel, JM; Press, OW; Rajendran, JG; Rezvani, AR; Sandmaier, BM; Sorror, ML; Storb, RF; Storer, BE | 1 |
| Choi, YS; Jeon, YW; Kim, DY; Kim, HJ; Kim, JH; Kim, YJ; Lee, JH; Lee, JW; Lee, KH; Lee, S; Lee, SE; Min, CK; Min, WS; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Aldenhoven, M; Bierings, MB; Boelens, JJ; Bonney, D; Borrill, RE; Coussons, M; Jones, SA; Mercer, J; van der Ploeg, AT; van Hasselt, PM; Versluys, B; Wijburg, FA; Wynn, RF | 1 |
| Arcese, W; Barba, P; Esquirol, A; Gayoso, J; Guidi, S; Martino, R; Montesinos, P; Moscardó, F; Parody, R; Picardi, A; Piñana, JL; Sanz, G; Sanz, J; Sanz, MA; Sierra, J; Solano, C; Terol, MJ | 1 |
| Fuji, S; Fukuda, T; Hagiwara, S; Hatanaka, K; Hidaka, M; Ito, T; Kim, SW; Kurosawa, S; Nakamae, H; Ohashi, K; Takami, A; Yamaguchi, T; Yamashita, T; Yano, S | 1 |
| Bhargava, S; Chakrabarti, A; Chakrabarti, S; Chatterjee, S; Jaiswal, SR; O'Donnell, P; Ray, K | 1 |
| Abramovici, O; Carlos Molano, L; Cuvelier, A; Darmon, A; Duval-Modeste, AB; Louvel, JP; Muir, JF; Piton, N | 1 |
| Hong, DS; Ji, YS; Kim, CK; Kim, HJ; Kim, KH; Kim, SH; Lee, KT; Lee, MS; Min, CW; Park, SK; Won, JH; Yun, J | 1 |
| Agovi, MA; Bacigalupo, A; Bahlis, NJ; Ballen, K; Bredeson, CN; Brown, C; Chaudhry, MA; Horowitz, MM; Kurian, S; Muehlenbien, CE; Quinlan, D; Rizzo, JD; Russell, JA; Savoie, L; Stewart, DA; Zhang, MJ | 1 |
| Cao, TM; Franke, GN; Gyurkocza, B; Hoppe, R; Lange, T; Leisenring, W; Maloney, DG; Negrin, RS; Sandmaier, BM; Shizuru, JA; Sorror, M; Storb, RF | 1 |
| Bojarska-Junak, A; Chocholska, S; Dmoszynska, A; Klimek, P; Kowal, M; Podhorecka, M | 1 |
| Chakraverty, R; Denovan, S; Fielding, AK; Hough, R; Kottaridis, PD; Linch, DC; Mackinnon, S; Mead, AJ; Mohamedbhai, S; Morris, EC; Orti, G; Peggs, KS; Thomson, KJ | 1 |
| Brewer, SC; Cleveland, KO; Gelfand, MS | 1 |
| Baron, F; Beguin, Y; Castermans, E; Cheynier, R; Dutrieux, J; Geenen, V; Gothot, A; Hannon, M; Humblet-Baron, S; Sandmaier, BM; Seidel, L; Storb, R; Vanbellinghen, JF; Willems, E | 1 |
| Ariga, T; Cho, Y; Ichikawa, M; Iguchi, A; Inamoto, J; Kaneda, M; Kawamura, N; Kobayashi, I; Kobayashi, R; Ohkura, Y; Ohshima, J; Sato, T; Takezaki, SI; Yamada, M | 1 |
| Gupta, V; Hayden, J; Ho, AY; Ireland, RM; Islam, MS; Koh, MB; Lim, Z; Marks, DI; Marsh, JC; Mufti, GJ; Pagliuca, A; Potter, V; Russell, N | 1 |
| Boudova, L; Jindra, P; Karas, M; Kazakov, D; Koza, V; Svoboda, T; Vokurka, S | 1 |
| Baxter-Lowe, LA; Cowan, MJ; Dvorak, CC; Horn, B; Law, J; Long-Boyle, JR; Musick, L | 1 |
| Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R | 1 |
| Anxionnat, R; Grignon, Y; Hulin, C; Léonard, S; Taillandier, L; Vespignani, H | 1 |
| Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P | 1 |
| Kami, M; Kanda, Y; Makimoto, A; Mineishi, S; Nakai, K; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H | 1 |
| Bardou, VJ; Bay, JO; Bilger, K; Blaise, D; Boiron, JM; Braud, AC; Cahn, JY; Chabannon, C; Choufi, B; Faucher, C; Fleury, J; François, S; Gratecos, N; Gravis, G; Maraninchi, D; Michallet, M; Mohty, M; Sotto, JJ; Viens, P; Viret, F | 1 |
| Casper, J; Dölken, G; Freund, M; Hammer, U; Hartung, G; Kiefer, T; Kleine, HD; Knauf, W; Knopp, A; Steiner, B; Wegener, R; Wilhelm, S; Wolff, D | 1 |
| Dumontet, C; Fernández-Calotti, P; Galmarini, CM; Gamberale, R; Geffner, J; Giordano, M; Jordheim, L; Sánchez-Avalos, J | 1 |
| Beelen, D; Bornhäuser, M; Ehninger, G; Fauser, AA; Held, TK; Kiehl, M; Kröger, N; Runde, V; Schetelig, J; Schwerdtfeger, R; Siegert, W; Thiede, C; Zabelina, T; Zander, A | 1 |
| Abe, Y; Choi, I; Inaba, S; Matsushima, T; Muta, K; Nagasawa, E; Nawata, H; Nishimura, J; Ohtsuka, R; Tachikawa, Y | 1 |
| Alegre, A; Ayuk, F; Beyer, J; Brand, R; Fauser, A; Kiehl, M; Klingemann, H; Kröger, N; Leon, A; Martino, R; Myint, H; Nagler, A; Perez-Simon, JA; San Miguel, JF; Sayer, HG; Schwerdtfeger, R; Shimoni, A; Tomas, JF; Zabelina, T; Zander, AR | 1 |
| Fabbri, A; Forconi, F; Gozzetti, A; Lauria, F; Lenoci, M; Marotta, G; Raspadori, D | 1 |
| Cao, TM; Grumet, FC; Johnston, LJ; Laport, GG; Lowsky, R; Negrin, RS; Sheehan, K; Shizuru, JA; Stockerl-Goldstein, KE; Stuart, MJ; Wong, RM | 1 |
| Lennard, AL; Osborne, WL | 1 |
| Claxton, DF; Ehmann, C; Rybka, W | 1 |
| Auerbach, AD; Defor, TE; Macmillan, ML; Slungaard, A; Tan, PL; Wagner, JE | 1 |
| Austin, H; Balow, JE; Barrett, J; Childs, R; Geller, N; Igarashi, T; Lundqvist, A; Sabnis, S; Srinivasan, R; Takahashi, Y; Tisdale, J | 1 |
| Barkholt, L; Hassan, Z; Mattsson, J; Omazic, B; Remberger, M; Ringdén, O; Sairafi, D; Uzunel, M | 1 |
| Emmons, RV; Jillella, AP; Klumpp, TR; Mangan, KF; Shafer, D | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, CC; Kim, DW; Kim, HJ; Kim, SY; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Grosskreutz, C; Isola, L; Osman, K; Scigliano, E | 1 |
| Bernal, MT; Besalduch, J; Brunet, MS; Caballero, D; Carrera, D; Ferra, C; Martin, J; Martino, R; Moraleda, JM; Nieto, JB; Perez-Simón, JA; Piñana, JL; Ribera, JM; Sampol, A; Sierra, J; Valcárcel, D; Vazquez, L | 1 |
| Fukuda, T; Heike, Y; Kato, R; Kim, S; Koido, K; Maruyama, D; Mori, S; Takaue, Y; Tanosaki, R; Teshima, T; Tobinai, K; Usui, E; Yamasaki, S | 1 |
| Kim, HS; Niihara, Y; Yospur, L | 1 |
| Ballerini, F; Beltrami, G; Bruni, R; Canepa, L; Cavaliere, M; Celesti, L; Clavio, M; Congiu, M; Damasio, E; Gobbi, M; Miglino, M; Nati, S; Pierri, I; Pietrasanta, D; Rossi, E; Santini, G; Spriano, M; Vallebella, E; Vimercati, R | 1 |
| Blanche, P; Bouscary, D; Dreyfus, F; Gombert, B; Sicard, D; Stieltjes, N | 1 |
| Anderlini, P; Andersson, BS; Andreeff, M; Braunschweig, I; Bruton, J; Champlin, R; Claxton, D; Cohen, A; Davis, M; Donato, M; Gajewski, J; Giralt, S; Ippolitti, C; Khouri, I; Kornblau, S; Molldrem, J; Przepiorka, D; Thall, PF; Ueno, NT; Wang, X | 1 |
| Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Geissler, G; Helwig, A; Jenke, A; Lutterbeck, K; Oelschlagel, U; Platzbecker, U; Plettig, R; Röllig, C; Thiede, C | 1 |
| Bargay, J; Caballero, MD; Canals, C; Conde, JG; Léon, A; Martino, R; Odriozola, J; Rayón, C; San Miguel, J; Sarrá, J; Sierra, J; Simón, JA; Solano, C; Urbano-Ispízua, A | 1 |
19 trial(s) available for fludarabine and Chronic Disease
| Article | Year |
|---|---|
Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study.
Topics: Acute Disease; Adolescent; Adult; Aged; Allografts; Anemia, Aplastic; Antilymphocyte Serum; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2020 |
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Recurrence; Remission Induction; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Vidarabine | 2017 |
Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen.
Topics: Acute Disease; Adult; Allografts; Antilymphocyte Serum; beta-Thalassemia; Busulfan; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Infant; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Risk Factors; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2019 |
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
Topics: Adult; Aged; Allografts; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine | 2019 |
Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.
Topics: Adult; Aged; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Agents; Bone Marrow Diseases; Bone Marrow Failure Disorders; Child; Chronic Disease; Cyclosporine; Female; Graft Rejection; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hemoglobinuria, Paroxysmal; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Peripheral Blood Stem Cell Transplantation; Risk Factors; Salvage Therapy; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematologic Diseases; Humans; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Pilot Projects; Survival Rate; Time Factors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2014 |
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Chronic Disease; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Myeloablative Agonists; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Yttrium Radioisotopes | 2015 |
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Herpesvirus 4, Human; Hodgkin Disease; Humans; Infectious Mononucleosis; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine | 2016 |
A prospective multicenter study of unrelated bone marrow transplants using a reduced-intensity conditioning regimen with low-dose ATG-F.
Topics: Adult; Aged; Allografts; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Incidence; Male; Middle Aged; Prospective Studies; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2016 |
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning.
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Vidarabine | 2016 |
Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.
Topics: Adolescent; Adult; Alemtuzumab; Anemia, Aplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Chronic Disease; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Busulfan; Child; Child, Preschool; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Infant; Myeloablative Agonists; Neutrophils; Prospective Studies; Secondary Prevention; Severity of Illness Index; Survival Analysis; T-Lymphocytes; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2012 |
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2013 |
Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Busulfan; Chronic Disease; Family; Female; Histocompatibility Testing; Humans; Immunosuppressive Agents; Leukemia; Living Donors; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Treatment Outcome; Vidarabine | 2004 |
The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Topics: Acute Disease; Adenosine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cladribine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chronic Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Natural; Male; Middle Aged; Neoplasms; Pneumonia; Survival Analysis; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2001 |
37 other study(ies) available for fludarabine and Chronic Disease
| Article | Year |
|---|---|
[Cutaneous complications following hematopoietic stem cell transplantation].
Topics: Acute Disease; Adolescent; Adult; Allografts; Busulfan; Candidiasis; Chickenpox; Child; Chronic Disease; Dermatomycoses; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Herpes Genitalis; Humans; Induction Chemotherapy; Malassezia; Male; Melphalan; Middle Aged; Morocco; Prospective Studies; Skin Diseases; Skin Diseases, Infectious; Vidarabine; Young Adult | 2021 |
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoprevention; Chronic Disease; Disease Progression; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Recurrence; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Successful hematopoietic reconstitution by unrelated donor cord blood transplantation in children with Fanconi anemia: report of 3 cases.
Topics: Animals; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Fanconi Anemia; Graft vs Host Disease; Hematopoiesis; Histocompatibility Testing; Humans; Immunosuppressive Agents; Infant; Male; Myeloablative Agonists; Rabbits; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Female; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Isogeneic; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2015 |
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Mucopolysaccharidoses; Myeloablative Agonists; Neurodegenerative Diseases; Practice Guidelines as Topic; Prognosis; Recurrence; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
[Chronic alveolar condensations with erythematous cutaneous lesions].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Deoxycytidine; Diagnosis, Differential; Doxorubicin; Erythema; Female; Gemcitabine; Humans; Lung Neoplasms; Mycosis Fungoides; Pulmonary Alveoli; Skin Neoplasms; Vidarabine | 2016 |
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Kaplan-Meier Estimate; Living Donors; Male; Middle Aged; Myeloablative Agonists; Proportional Hazards Models; Recurrence; Republic of Korea; Retrospective Studies; Risk Factors; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2016 |
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.
Topics: Acute Disease; Adolescent; Adult; Aged; Anemia, Aplastic; Child; Chronic Disease; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Living Donors; Male; Middle Aged; Myeloablative Agonists; Neoplasms; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2009 |
Assessment of peripheral blood and bone marrow cells apoptosis caused by purine analogues in patients with chronic lymphocytic leukemia in correlation with parameters of disease progression.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Apoptosis; B-Lymphocyte Subsets; bcl-2-Associated X Protein; Biomarkers; Bone Marrow Cells; Caspase 3; Chronic Disease; Cladribine; Disease Progression; Enzyme Activation; Humans; Leukemia, Lymphoid; Membrane Glycoproteins; Prognosis; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2010 |
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Chronic Disease; Disease-Free Survival; Female; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Living Donors; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2010 |
Rhodococcus equi pneumonia in a patient with fludarabine-treated chronic lymphocytic leukemia and CD4-lymphopenia.
Topics: Actinomycetales Infections; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; CD4 Lymphocyte Count; Chronic Disease; Female; Humans; Leukemia, Lymphoid; Lymphopenia; Opportunistic Infections; Pneumonia, Bacterial; Rhodococcus equi; Vidarabine | 2010 |
Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Chronic Disease; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prognosis; Receptors, Antigen, T-Cell; Survival Rate; T-Lymphocytes; Thymus Gland; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
Successful reduced-intensity SCT from unrelated cord blood in three patients with X-linked SCID.
Topics: Acute Disease; Antineoplastic Agents; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantation; Female; Fetal Blood; Graft vs Host Disease; Histocompatibility Testing; Humans; Infant; Lung Diseases, Fungal; Male; Pneumonia, Bacterial; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; X-Linked Combined Immunodeficiency Diseases | 2011 |
Significant oral graft-versus-host disease after allogeneic stem cell transplantation with the FLU/MEL conditioning regimen.
Topics: Acute Disease; Adult; Aged; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Melphalan; Middle Aged; Mouth Diseases; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2011 |
[Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia].
Topics: Aged; Antineoplastic Agents; Biopsy; Brain; Chronic Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Multifocal; Male; Polymerase Chain Reaction; Vidarabine | 2002 |
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Life Tables; Lymphocyte Transfusion; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Recurrence; Risk Factors; Siblings; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Middle Aged; Proportional Hazards Models; Recurrence; Stem Cell Transplantation; Survival Rate; Thyroglobulin; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2003 |
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; Disease Progression; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Siblings; Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine.
Topics: Aged; Aged, 80 and over; Apoptosis; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Survival; Cells, Cultured; Chronic Disease; Female; Humans; Immunosuppressive Agents; Leukemia, B-Cell; Male; Middle Aged; Statistics, Nonparametric; Vidarabine | 2003 |
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Recurrence; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Vidarabine | 2004 |
Successful treatment with nonmyeloablative allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia complicated with pulmonary infection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Combined Modality Therapy; Cyclosporine; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pneumonia; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose.
Topics: Adult; Aged; Antigens, CD; CD8-Positive T-Lymphocytes; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Histocompatibility Testing; Humans; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2005 |
Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath 1H) or fludarabine.
Topics: Acute Kidney Injury; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chronic Disease; Disseminated Intravascular Coagulation; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Renal Dialysis; Transplantation Conditioning; Vidarabine | 2005 |
Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Disease Progression; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Middle Aged; Sirolimus; Survival Analysis; Treatment Outcome; Vidarabine | 2005 |
Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chronic Disease; Cyclophosphamide; Cyclosporine; Fanconi Anemia; Female; Fetal Blood; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methylprednisolone; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Survival Rate; T-Lymphocytes; Treatment Outcome; Vidarabine | 2006 |
Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Chronic Disease; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Glomerulus; Male; Middle Aged; Nephrotic Syndrome; Proteinuria; T-Lymphocytes; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2005 |
Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning.
Topics: Acute Disease; Antifungal Agents; Cause of Death; Chronic Disease; Cyclosporine; Cytomegalovirus Infections; Graft Rejection; Graft vs Host Disease; Humans; Immunosuppressive Agents; Mycoses; Siblings; Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Treatment Outcome; Vidarabine | 2006 |
Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chimerism; Chronic Disease; Cohort Studies; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Humans; Injections, Intravenous; Lymphocyte Transfusion; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2007 |
Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin.
Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Topics: Adult; Aged; Busulfan; Chronic Disease; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Multivariate Analysis; Myeloablative Agonists; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.
Topics: Adolescent; Adult; Aged; Aspergillosis; Bacteremia; Busulfan; Catheterization, Central Venous; Chronic Disease; Communicable Diseases; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pneumonia, Bacterial; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
Chronic lymphocytic leukemia in a patient with sickle cell anemia.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Chronic Disease; Fatal Outcome; Hepatitis B; Hepatitis C; Humans; Immunoglobulins; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1998 |
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease.
Topics: Adult; Aged; Antineoplastic Agents; Chronic Disease; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasm, Residual; Treatment Outcome; Vidarabine | 1998 |
Successful treatment of acquired factor VIII inhibitor with fludarabine and cyclophosphamide in chronic lymphoid leukemia.
Topics: Aged; Antibodies; Chronic Disease; Cyclophosphamide; Factor VIII; Female; Hemorrhage; Humans; Immunosuppressive Agents; Leukemia, Lymphoid; Vidarabine | 1999 |
Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study.
Topics: Adolescent; Adult; Aged; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Karyotyping; Lymphoproliferative Disorders; Male; Middle Aged; Prognosis; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |